AR066617A1 - Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y emfermedades asociadas con angiogenesis - Google Patents
Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y emfermedades asociadas con angiogenesisInfo
- Publication number
- AR066617A1 AR066617A1 ARP080102099A ARP080102099A AR066617A1 AR 066617 A1 AR066617 A1 AR 066617A1 AR P080102099 A ARP080102099 A AR P080102099A AR P080102099 A ARP080102099 A AR P080102099A AR 066617 A1 AR066617 A1 AR 066617A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- halogen
- alkyl
- hydrogen
- heterocyclyl
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title abstract 2
- 230000003463 hyperproliferative effect Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 12
- 229910052736 halogen Inorganic materials 0.000 abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 10
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 239000001257 hydrogen Substances 0.000 abstract 9
- 150000002367 halogens Chemical class 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000004104 aryloxy group Chemical group 0.000 abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 abstract 2
- 125000002950 monocyclic group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 125000003435 aroyl group Chemical group 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 abstract 1
- -1 heteroaryl substituted pyrazole compounds Chemical class 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a compuestos de pirazol sustituidos con heteroarilo, a composiciones farmacéuticas que contienen estos compuestos y al uso de estos compuestos o composiciones para tratar trastornos hiperproliferativos y/o angiogénesis, comoun unico agente o en combinacion con otros ingredientes activos o medidas terapéuticas. Reivindicacion 1: Un compuesto que tiene la formula (1), o una de sus sales, solvatos, hidratos o estereoisomeros fisiologicamente aceptables, en la que: A esheteroarilo opcionalmente sustituido con halogeno o fenilo o es heterociclilo; n es un numero entero de 0-3; R1 en cada aparicion es, de modo independiente, halogeno, -NR6C(O)R7, -C(O)R6, -C(O)OR6, -OC(O)R6, -OR6, -SR6, -S(O)R6, -SO2R6, ciano,nitro, -C(O)NR6R7, -SO2NR6R7 o -NR6R7, o R1 es, de modo independiente, arilo, heteroarilo, heterociclilo, alquilo o cicloalquilo, cada uno opcionalmente sustituido con uno o varios grupos halogeno, OR6 o NR6R7; R2 es arilo opcionalmente sustituidocon 1, 2 o 3 grupos R8 o heteroarilo opcionalmente sustituido con 1, 2 o 3 grupos R8, cuando A es heteroarilo mono- o bicíclico o heterociclilo mono- o bicíclico, o R2 es hidrogeno, halogeno, ciano, alquil opcionalmente sustituido con hasta 3 átomosde fluor, alquiloxi opcionalmente sustituido con hasta 3 átomos de fluor, cicloalquilo, ariloxi, aroílo, aralquilo opcionalmente sustituido con halogeno, o heterociclilo opcionalmente sustituido con alquilo, cuando A es heteroarilo bi- o tricíclicoo heterociclilo mono-, bi- o tricíclico; R3 y R4 son cada uno, de modo independiente, hidrogeno, halogeno, -OR6, -SR6, -NR6R7, alquilo opcionalmente sustituido con uno o varios grupos halogeno, R6, -OR6 o -NR6R7, o cicloalquilo opcionalmentesustituido con uno o varios grupos halogeno, R6, -OR6 o -NR6R7; R5 es hidrogeno, oxo o alquilo opcionalmente sustituido con uno o varios grupos halogeno, -OR6 o -NR6R7; cada aparicion de R6 o R7 puede ser igual o diferente y es, de modoindependiente, hidrogeno, o arilo, heteroarilo, heterociclilo, alquilo o cicloalquilo, cada uno de los cuales puede estar opcionalmente sustituido con uno o varios grupos hidrogeno, halogeno, -OR9 o -NR9R10; cada aparicion de R8 puede ser igual odiferente y es, de modo independiente, hidrogeno, halogeno, -NR9C(O)R10, -NR9C(O)OR10, -C(O)R9, -C(O)OR9, -OC(O)R9, -OR9, -SR9, -S(O)R9, -SO2R9, ciano, nitro, -C(O)NR9R10, -SO2NR9R10, -NR9R10 o arilo, heteroarilo, heterociclilo, alquilo ocicloalquilo, cada uno de los cuales puede estar opcionalmente sustituido con uno o varios grupos halogeno, R11, -OR9 o -NR9R10; cada aparicion de R9 y R10 puede ser igual o diferente y es, de modo independiente, hidrogeno, o arilo, heteroarilo,heterociclilo, alquilo, cicloalquilo, aralquilo o heterociclilalquilo, cada uno de los cuales puede estar opcionalmente sustituido con uno o varios grupos hidrogeno, halogeno, hidroxilo, alquiloxi, cicloalquiloxi, ariloxi, amino, alquilamino,cicloalquilamino, arilamino, alquilo, cicloalquilo, alquilcarbonilo o alcoxicarbonilo; cada aparicion de R11 puede ser igual o diferente y es, de modo independiente, hidrogeno, oxo, arilo, heteroarilo, heterociclilo, alquilo, cicloalquilo, -C(O)R9, -C(O)OR9, -NR12C(O)R13, -N[C(O)R13]2, -NR12C(O)OR13 o -N[C(O)OR13]2; R12 es hidrogeno o alquilo; y R13 es alquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93081607P | 2007-05-18 | 2007-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066617A1 true AR066617A1 (es) | 2009-09-02 |
Family
ID=39760483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102099A AR066617A1 (es) | 2007-05-18 | 2008-05-16 | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y emfermedades asociadas con angiogenesis |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8796253B2 (es) |
| EP (1) | EP2148877A2 (es) |
| JP (1) | JP5702138B2 (es) |
| KR (1) | KR20100016617A (es) |
| CN (1) | CN101765596B (es) |
| AR (1) | AR066617A1 (es) |
| AU (1) | AU2008253311A1 (es) |
| BR (1) | BRPI0812361A2 (es) |
| CA (1) | CA2687306A1 (es) |
| CL (1) | CL2008001372A1 (es) |
| IL (1) | IL201537A0 (es) |
| MX (1) | MX2009012000A (es) |
| PA (1) | PA8780201A1 (es) |
| PE (1) | PE20090297A1 (es) |
| RU (1) | RU2009146851A (es) |
| TW (1) | TW200909428A (es) |
| UY (1) | UY31080A1 (es) |
| WO (1) | WO2008141731A2 (es) |
| ZA (1) | ZA200907999B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2011123672A (ru) * | 2008-11-14 | 2012-12-20 | Байер Шеринг Фарма Акциенгезельшафт | Гетероароматические соединения для применения в качестве hif ингибиторов |
| DE102009041242A1 (de) | 2009-09-11 | 2011-12-15 | Bayer Schering Pharma Aktiengesellschaft | Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102009041241A1 (de) | 2009-09-11 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Substituierte Aryl-Verbindungen und ihre Verwendung |
| DE102008057344A1 (de) * | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung |
| EP2356113B1 (de) * | 2008-11-14 | 2015-01-07 | Bayer Intellectual Property GmbH | Heterocyclisch substituierte aryl-verbindungen als hif-inhibitoren |
| DK2382215T3 (da) * | 2008-12-29 | 2014-10-27 | Sanofi Sa | Derivater af 2-pyridin-2-yl-pyrazol-3(2h)-on, fremstilling og terapeutisk anvendelse heraf |
| FR2940652B1 (fr) * | 2008-12-29 | 2011-02-11 | Sanofi Aventis | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique |
| JP5734870B2 (ja) | 2008-12-29 | 2015-06-17 | サノフイ | ２−ピリジン−２−イル−ピラゾール−３（２ｈ）−オンの誘導体、これらの調製およびｈｉｆ活性化剤としての治療用途 |
| US8389509B2 (en) | 2009-01-23 | 2013-03-05 | Bristol-Myers Squibb Company | Substituted pyrazole compounds |
| WO2010085582A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| WO2010085581A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| US8242284B1 (en) * | 2009-09-21 | 2012-08-14 | The United States Of America As Represented By The United States Department Of Energy | Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making |
| US8680098B2 (en) | 2010-03-05 | 2014-03-25 | Janssen Pharmaceutica, Nv | Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators |
| CN101805338B (zh) * | 2010-04-06 | 2014-10-15 | 沈阳药科大学 | 噁二唑基哌嗪衍生物及其用途 |
| CN103119038B (zh) * | 2010-04-23 | 2016-05-04 | 百时美施贵宝公司 | 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1，2，4-噁二唑基-3-基)扁桃酰胺 |
| WO2011141325A1 (de) | 2010-05-08 | 2011-11-17 | Bayer Pharma Aktiengesellschaft | Hydroxyalkylbenzyl- pyrazole und ihre verwendung zur behandlung von hyperproliferativen und angiogenen erkrankungen |
| AU2011252223A1 (en) * | 2010-05-08 | 2012-12-06 | Bayer Intellectual Property Gmbh | Substituted heterocyclyl benzyl pyrazoles, and use thereof |
| EP2390252A1 (en) * | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| CN103313976B (zh) | 2010-06-30 | 2016-11-23 | 铁木医药有限公司 | sGC刺激物 |
| RU2016101964A (ru) | 2010-11-09 | 2018-11-21 | Айронвуд Фармасьютикалз, Инк. | СТИМУЛЯТОРЫ sGC |
| MX2013014310A (es) * | 2011-06-06 | 2014-01-23 | Akebia Therapeutics Inc | Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer. |
| NO2686520T3 (es) | 2011-06-06 | 2018-03-17 | ||
| UY34200A (es) | 2011-07-21 | 2013-02-28 | Bayer Ip Gmbh | 3-(fluorovinil)pirazoles y su uso |
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| US20140329797A1 (en) | 2011-10-17 | 2014-11-06 | Bayer Intellectual Property Gmbh | Substituted oxadiazolyl pyridinones and oxadiazolyl pyridazinones as hif inhibitors |
| EP3112363A1 (en) | 2011-12-27 | 2017-01-04 | Ironwood Pharmaceuticals, Inc. | 2-[1-[(2-fluorophenyl)methyl]-5-(3-isoxazolyl)-1h-pyrazol-3-yl]-pyrimidine derivatives and related compounds as soluble guanylate cyclase (sgc) stimulators for the treatment of pulmonary hypertension |
| US20140073634A1 (en) * | 2012-08-24 | 2014-03-13 | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center | Heterocyclic modulators of hif activity for treatment of disease |
| WO2014031933A2 (en) * | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
| AU2013305633B2 (en) * | 2012-08-24 | 2018-03-08 | Board Of Regents, The University Of Texas System | Heterocyclic modulators of HIF activity for treatment of disease |
| WO2014121654A1 (zh) * | 2013-02-05 | 2014-08-14 | 山东轩竹医药科技有限公司 | 四并环激酶抑制剂 |
| TW201444798A (zh) | 2013-02-28 | 2014-12-01 | 必治妥美雅史谷比公司 | 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物 |
| EP2961746B1 (en) | 2013-02-28 | 2018-01-03 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors |
| CA2914662C (en) | 2013-06-13 | 2022-05-31 | Robert Shalwitz | Compositions and methods for treating anemia |
| EP2853532B1 (en) * | 2013-09-28 | 2020-12-09 | Instytut Farmakologii Polskiej Akademii Nauk | 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III |
| US20150105252A1 (en) * | 2013-10-15 | 2015-04-16 | E I Du Pont De Nemours And Company | Substituted pyrazoles as herbicides |
| ES2726648T3 (es) | 2014-02-25 | 2019-10-08 | Univ Texas | Sales de moduladores heterocíclicos de la actividad del HIF para el tratamiento de enfermedades |
| AU2015316796A1 (en) | 2014-09-19 | 2017-03-30 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as Bub1 inhibitors |
| WO2016118858A1 (en) | 2015-01-23 | 2016-07-28 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| PE20180189A1 (es) | 2015-04-01 | 2018-01-23 | Akebia Therapeutics Inc | Composiciones y metodos para el tratamiento de la anemia |
| CN106366078A (zh) * | 2015-07-24 | 2017-02-01 | 浙江大学 | 吲唑-噁二唑类衍生物、含其的药物组合物及其在抗肿瘤中的应用 |
| WO2017039318A1 (en) * | 2015-09-01 | 2017-03-09 | Kainos Medicine, Inc. | Benzimidazole derivatives for dna methylation inhibitors |
| CN108164520B (zh) * | 2018-01-15 | 2021-03-19 | 东南大学 | 缺氧抑制剂与抗肿瘤药物的偶联化合物及其制备和应用 |
| MX2020011845A (es) | 2018-05-09 | 2021-01-15 | Akebia Therapeutics Inc | Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico. |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| CN110257393A (zh) * | 2019-06-28 | 2019-09-20 | 西安医学院 | 翻译后水平低氧调控基因、应用及其调控方法 |
| CN112110908A (zh) * | 2020-09-25 | 2020-12-22 | 山东大学 | 一种1,3-二取代吲唑类化合物及其制备方法和应用 |
| CN112426422A (zh) * | 2020-12-02 | 2021-03-02 | 安徽医科大学 | 吡啶甲酰胺衍生物AMSP-30m在制备防治类风湿关节炎药物中的应用 |
| WO2022131146A1 (ja) * | 2020-12-17 | 2022-06-23 | 国立大学法人京都大学 | 含窒素複素環式化合物 |
| WO2024067708A1 (zh) * | 2022-09-30 | 2024-04-04 | 苏州阿尔脉生物科技有限公司 | 草酸胺类衍生物、包含其的药物组合物及其医药用途 |
| CN117800894A (zh) * | 2022-09-30 | 2024-04-02 | 苏州阿尔脉生物科技有限公司 | 饱和环类衍生物、包含其的药物组合物及其医药用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19744026A1 (de) * | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| GB0002666D0 (en) | 2000-02-04 | 2000-03-29 | Univ London | Blockade of voltage dependent sodium channels |
| ATE300540T1 (de) * | 2000-04-27 | 2005-08-15 | Yamanouchi Pharma Co Ltd | Imidazopyridin-derivate |
| MXPA03011196A (es) | 2001-06-08 | 2004-10-28 | Cytovia Inc | 3-aril-5-aril-[1,2,4]-oxadiazoles sustituidos y analogos. |
| US6610726B2 (en) * | 2001-06-29 | 2003-08-26 | North Shore-Long Island Jewish Research Institute | Compositions and agents for modulating cellular proliferation and angiogenesis |
| US7569592B2 (en) | 2001-12-18 | 2009-08-04 | Merck & Co., Inc. | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| PL377461A1 (pl) | 2002-12-20 | 2006-02-06 | Pharmacia Corporation | Acykliczne związki pirazolu do hamowania kinazy białkowej 2 aktywowanej przez kinazę białkową aktywowaną mitogenem |
| CN100387594C (zh) | 2003-04-03 | 2008-05-14 | 麦克公司 | 二芳基取代的吡唑类代谢型谷氨酸受体-5调节剂 |
| CA2530679A1 (en) * | 2003-06-30 | 2005-04-07 | Hif Bio, Inc. | Compounds for treating angiogenesis |
| US8329703B2 (en) | 2005-02-15 | 2012-12-11 | Xtl Biopharmaceuticals Ltd. | Pyrazole compounds |
| GB0508472D0 (en) * | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| AU2006261841B8 (en) * | 2005-06-27 | 2012-12-06 | Exelixis Patent Company Llc | Pyrazole based LXR modulators |
| WO2007034279A2 (en) | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | C3a antagonists and pharmaceutical compositions thereof |
| AU2011252223A1 (en) * | 2010-05-08 | 2012-12-06 | Bayer Intellectual Property Gmbh | Substituted heterocyclyl benzyl pyrazoles, and use thereof |
-
2008
- 2008-05-08 RU RU2009146851/04A patent/RU2009146851A/ru not_active Application Discontinuation
- 2008-05-08 CA CA002687306A patent/CA2687306A1/en not_active Abandoned
- 2008-05-08 MX MX2009012000A patent/MX2009012000A/es not_active Application Discontinuation
- 2008-05-08 CN CN200880015925.6A patent/CN101765596B/zh not_active Expired - Fee Related
- 2008-05-08 EP EP20080758408 patent/EP2148877A2/en not_active Withdrawn
- 2008-05-08 AU AU2008253311A patent/AU2008253311A1/en not_active Abandoned
- 2008-05-08 KR KR1020097023930A patent/KR20100016617A/ko not_active Application Discontinuation
- 2008-05-08 JP JP2010508718A patent/JP5702138B2/ja not_active Expired - Fee Related
- 2008-05-08 WO PCT/EP2008/003681 patent/WO2008141731A2/en active Application Filing
- 2008-05-08 US US12/600,640 patent/US8796253B2/en not_active Expired - Fee Related
- 2008-05-08 BR BRPI0812361-6A2A patent/BRPI0812361A2/pt not_active IP Right Cessation
- 2008-05-09 CL CL2008001372A patent/CL2008001372A1/es unknown
- 2008-05-09 UY UY31080A patent/UY31080A1/es not_active Application Discontinuation
- 2008-05-12 PA PA20088780201A patent/PA8780201A1/es unknown
- 2008-05-12 PE PE2008000823A patent/PE20090297A1/es not_active Application Discontinuation
- 2008-05-16 AR ARP080102099A patent/AR066617A1/es not_active Application Discontinuation
- 2008-05-16 TW TW097117928A patent/TW200909428A/zh unknown
-
2009
- 2009-10-15 IL IL201537A patent/IL201537A0/en unknown
- 2009-11-13 ZA ZA2009/07999A patent/ZA200907999B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5702138B2 (ja) | 2015-04-15 |
| KR20100016617A (ko) | 2010-02-12 |
| PE20090297A1 (es) | 2009-03-27 |
| PA8780201A1 (es) | 2009-02-09 |
| IL201537A0 (en) | 2010-05-31 |
| UY31080A1 (es) | 2009-01-05 |
| CN101765596A (zh) | 2010-06-30 |
| WO2008141731A3 (en) | 2009-03-26 |
| TW200909428A (en) | 2009-03-01 |
| EP2148877A2 (en) | 2010-02-03 |
| WO2008141731A2 (en) | 2008-11-27 |
| US20100249085A1 (en) | 2010-09-30 |
| ZA200907999B (en) | 2011-06-29 |
| CN101765596B (zh) | 2015-04-29 |
| CL2008001372A1 (es) | 2008-12-05 |
| BRPI0812361A2 (pt) | 2015-02-03 |
| US8796253B2 (en) | 2014-08-05 |
| CA2687306A1 (en) | 2008-11-27 |
| AU2008253311A1 (en) | 2008-11-27 |
| JP2010527378A (ja) | 2010-08-12 |
| MX2009012000A (es) | 2009-11-19 |
| RU2009146851A (ru) | 2011-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066617A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y emfermedades asociadas con angiogenesis | |
| AR047063A1 (es) | Heterociclos azabiciclicos como moduladores de receptor canabinoide | |
| PE20220597A1 (es) | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos | |
| CO5700778A2 (es) | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular | |
| CO5650164A2 (es) | Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
| AR050966A1 (es) | Derivados de bencimidazol utiles como moduladores selectivos de receptores de androgenos (sarms) | |
| AR043508A1 (es) | 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores | |
| AR046172A1 (es) | Pirazolopiridinas y sus analogos; composiciones farmaceuticas que los contienen y su uso en la inhibicion de la biosintesis de citocinas | |
| PE20050013A1 (es) | Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c | |
| AR062666A1 (es) | Benzotriazoles como moduladores de quinasas | |
| AR010740A1 (es) | Compuestos derivados de pirimidina biciclica condensada, composicion farmaceutica que los contiene y procedimiento de tratamiento que utilizadichos compuestos | |
| AR083169A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR073450A1 (es) | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar | |
| AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
| AR036492A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes | |
| PE20060583A1 (es) | Tiazolil-dihidro-indazoles como inhibidores de pi3-quinasas | |
| AR062499A1 (es) | Derivados de n-fenil pirazol y piridil pirazoles, composiciones farmaceuticas que los contienen y usos como agentes antiagregantes plaquetarios y antitromboticos. | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| AR086636A1 (es) | Ligandos sigma utiles para tratar y/o prevenir el dolor asociado a la diabetes tipo 2 y composiciones farmaceuticas que los contienen | |
| PE20040479A1 (es) | Inhibidores de proteasa del vih y composiciones que los contienen | |
| CL2019002919A1 (es) | Compuestos inhibidores vmat2 y composiciones relacionadas. | |
| AR112900A1 (es) | Compuesto derivado de pirazol y uso de este | |
| AR061643A1 (es) | Derivados de ureas de piperidina o pirrolidina, metodos para su preparacion, una composicion farmaceutica que los comprende y el empleo de estos en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la enzima 11beta-hsd1. | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR054208A1 (es) | Derivados de oxopiperidina, su preparacion, una composicion farmaceutica y compuestos intermediarios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |